Jinghua Pharmaceutical Group Co., Ltd.

002349

CNE100000L14

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 12/05/2024 BST			5-day change	1st Jan Change
7.89 ^CNY	-1.00%		+0.13%	-11.05%

04-29	Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-18	Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Jinghua Pharmaceutical Group Co., Ltd. Implements 2021 Final Profit Distribution Plan (A Shares), Payable on 13 June 2022

June 05, 2022

Jinghua Pharmaceutical Group Co., Ltd. implemented 2021 final profit distribution plan (A shares) of Cash dividend/10 shares (tax included) CNY 0.60000000 payable on 13 June 2022. Record date is 10 June 2022. Ex-date is 13 June 2022.

Latest news about Jinghua Pharmaceutical Group Co., Ltd.

Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29	CI
Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-18	CI
Jinghua Pharmaceutical's Unit Shuts Down Amid Water Pollution Probe	04-18	MT
Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	29/10/23	CI
Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	25/08/23	CI
Jinghua Pharmaceutical Group Co., Ltd. Announces Cash Dividend for 2022, Payable on 9 June 2023	05/06/23	CI
Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	28/04/23	CI
Jinghua Pharmaceutical Group Co., Ltd. Proposes Final Dividend for the Year 2022	24/04/23	CI
Jinghua Pharmaceutical Group Co., Ltd. Approves Cash Dividend for the Year 2022	24/04/23	CI
Jinghua Pharmaceutical Group Co., Ltd. Proposes Final Cash Dividend for the Year 2022	30/03/23	CI
China COVID infection fears fuel medical stock bets	12/12/22	RE
Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	30/10/22	CI
Jinghua Pharmaceutical Group Co., Ltd.(XSEC:002349) added to S&P Global BMI Index	19/09/22	CI
Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	29/08/22	CI
Jinghua Pharmaceutical Group Co., Ltd. Implements 2021 Final Profit Distribution Plan (A Shares), Payable on 13 June 2022	05/06/22	CI
Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	28/04/22	CI
Jinghua Pharmaceutical Group Co., Ltd. Approves Profit Distribution for 2021	25/04/22	CI
Jinghua Pharmaceutical's Controlling Shareholder Plans to Cut 2% Stake	08/04/22	CI
Jinghua Pharmaceutical Group Co., Ltd. Proposes Final Dividend for 2021	30/03/22	CI
Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	29/03/22	CI
Three Chinese Drugmakers Deny Receiving Orders From Pfizer	15/02/22	MT
Nantong Jinghua Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	26/10/21	CI
Haian Ruihai Urbanization Investment and Construction Co., Ltd., completed the acquisition of 10.29% stake in Nantong Jinghua Pharmaceutical Co., Ltd. from Zan Shengda.	18/10/21	CI
Jiangsu Qichen New Materials Co., Ltd. acquired 24.9% stake in Jiangsu Wannianchang Pharmaceutical Co., Ltd. from Nantong Jinghua Pharmaceutical Co., Ltd. for CNY 69.4 million.	28/09/21	CI
Nantong Jinghua Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2021, Payable 17 September 2021	03/09/21	CI

Chart Jinghua Pharmaceutical Group Co., Ltd.

Duration

Period

Chart Jinghua Pharmaceutical Group Co., Ltd.

More charts

Company Profile

JINGHUA PHARMACEUTICAL GROUP CO., LTD., formerly NANTONG JINGHUA PHARMACEUTICAL CO., LTD., is a China-based company, principally engaged in the research and development, production and distribution of Chinese patent drugs, pharm ingredients and intermediates and chemical intermediates. The Company is also engaged in the provision of traditional Chinese medicinal materials and Chinese herbal pieces, among others. The Company primarily provides tablets, capsules, pills, granules, injections, powder, syrup, healthcare products, beverages and chemical intermediates, among others. The Company offers Chinese patent medicines, such as Wangshi Baochiwan pills and Jidesheng tablets. Its bulk drugs include phenobarbitone and fluorouracil. The Company distributes its products in domestic and overseas markets.

Sector

Pharmaceuticals

Calendar

17/05/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JINGHUA PHARMACEUTICAL GROUP CO., LTD.	-11.05%	898M
ELI LILLY AND COMPANY	+29.42%	684B
NOVO NORDISK A/S	+30.34%	568B
JOHNSON & JOHNSON	-3.96%	361B
MERCK & CO., INC.	+17.83%	329B
ABBVIE INC.	+4.03%	284B
ASTRAZENECA PLC	+16.21%	240B
NOVARTIS AG	+9.66%	208B
ROCHE HOLDING AG	-6.83%	200B
AMGEN INC.	+6.86%	166B